Praxis reports Q2 2026 results, mid-cycle FDA meetings clear for two lead drugs

Praxis Precision Medicines reported second quarter 2026 results and a corporate update on August 6, 2026. The company said the mid-cycle meeting was successfully completed and the FDA identified no major safety or efficacy concerns to date, with the agency confirming that no advisory committee meeting is planned¹ for ulixacaltamide, which carries a PDUFA date of January 29, 2027.

The same held for relutrigine, where the mid-cycle meeting was successfully completed and the FDA identified no major safety or efficacy concerns to date, with the agency confirming that no advisory committee meeting is planned. Relutrigine's PDUFA date is December 27, 2026, after the FDA extended the review period following submission of additional sensitivity analyses of existing clinical data, which the FDA deemed a major amendment¹.

Praxis also disclosed that FDA Bioresearch Monitoring inspections covering quality, clinical operations, data integrity and safety for both ulixacaltamide and relutrigine were completed successfully, with no Form 483 issued¹. The company said it does not intend to communicate further regulatory updates on either application until the respective PDUFA dates¹.

Separately, elsunersen received its third Breakthrough Therapy Designation, based on positive results from the EMBRAVE Part A trial¹.

On financials, Praxis had $1.4 billion in cash, cash equivalents and marketable securities as of June 30, 2026, versus $926.1 million at December 31, 2025, expected to fund operations into 2028¹. Net loss for the quarter was $83.7 million, including $11.3 million of stock-based compensation, compared to $71.1 million a year earlier¹.